Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Expenses:
Research and development	$ 2,262,240	$ 3,726,132
General and administrative	2,896,444	2,706,394
Total operating expenses	5,158,684	6,432,526
Operating loss	(5,158,684)	(6,432,526)
Other income (expense):
Other income (expense), net	177,538	(44,395)
Interest expense	(3,295)	(158,928)
Other income (expense)	174,243	(203,323)
Loss from continuing operations before benefit from income taxes and noncontrolling interests	(4,984,441)	(6,635,849)
Benefit from income taxes	0	0
Net loss from continuing operations	(4,984,441)	(6,635,849)
Discontinued operations - net of taxes	0	(3,157,475)
Net loss	(4,984,441)	(9,793,324)
Less - net loss from continuing operations attributable to noncontrolling interests	(1,862)	(64,666)
Less - net loss from discontinued operations attributable to noncontrolling interests	0	(368,831)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	(4,982,579)	(9,359,827)
Amounts attributable to Caladrius Biosciences, Inc. common stockholders:
Loss from continuing operations	(4,982,579)	(6,571,183)
Loss from discontinued operations - net of taxes	0	(2,788,644)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,982,579)	$ (9,359,827)
Basic and diluted loss per share
Continuing operations (in usd per share)	$ (0.52)	$ (0.78)
Discontinued operations (in usd per share)	0.00	(0.33)
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.52)	$ (1.12)
Weighted average common shares outstanding:
Basic and diluted shares	9,557,347	8,386,903